Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 30, 2026

The introduction of hypomethylation agents and venetoclax into standard care for older patients with acute myeloid leukemia: A retrospective real-world analysis of feasibility, safety, and effectiveness from an outpatient hematology center.

View Full Paper
Ask AI
Bookmark
Share

Authors

HSH Tilman SteinmetzJWJan-Phillip Weber

Discussion

Loading...

Member takes

Overview

Retrospective study demonstrates prolonged survival with venetoclax plus hypomethylating agents in older acute myeloid leukemia patients, indicating feasible outpatient delivery.

Key Points

  • To evaluate the feasibility, safety, and clinical effectiveness of integrating venetoclax combined with hypomethylating agents into routine outpatient care for older patients with acute myeloid leukemia.
  • Retrospective single-center cohort study documenting all newly diagnosed acute myeloid leukemia patients (N=65) between January 2017 and April 2025.
  • Evaluated 43 older outpatient individuals (mean age 79.4 years, SD 5.86) receiving cytosine arabinoside (n=1), best supportive care (n=7), hypomethylating agent monotherapy (n=15), or hypomethylating agents with venetoclax (n=20).
  • Mean overall survival was 51.7 weeks (SD 49.09) with hypomethylating agents plus venetoclax, compared to 25.9 weeks (SD 28.87) with hypomethylating monotherapy and 19.6 weeks (SD 15.04) with best supportive care.
  • In the venetoclax combination cohort, zero patients developed tumor lysis syndrome, 11 patients (55%) developed an infection, and 14 patients (70%) required hospitalization during the initial two cycles.

Cite This Study

Steinmetz et al. (2026) studied this question.

synapsesocial.com/papers/6a93f08e6c1a8fb52e79cd46https://doi.org/10.1159/ort/aecag004
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients2024 · 2 citations
  2. 2Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study2026
  3. 3Venetoclax combined with hypomethylating agents for favorable risk acute myeloid leukemia: A single center experience.2024 · 1 citations
  4. 4Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight <scp>US</scp> academic centers2024 · 25 citations
  5. 5Real-World Effectiveness of First-Line Azacitidine or Decitabine with or without Venetoclax in AML Patients Unfit for Intensive Therapy2024